Current Liabilities
Other accrued liabilities
Royalty Pharma Other accrued liabilities decreased by 67.1% to $17.48M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.0%, from $18.60M to $17.48M. Over 5 years (FY 2020 to FY 2025), Other accrued liabilities shows an upward trend with a 23.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ3 2025
Last reportedQ1 2026
How to read this metric
Significant fluctuations may indicate changes in business model, such as shifts in deferred revenue recognition or changes in short-term regulatory obligations.
Detailed definition
This category includes miscellaneous short-term obligations that are not classified under accounts payable or accrued li...
Peer comparison
Commonly used as a catch-all for short-term liabilities; varies by industry and business model.
Metric ID:
current_liabilities_other_liabilities_currentHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.31M | $0.00 | $0.00 | $12.40M | $0.00 | $0.00 | $0.00 | $11.38M | $9.02M | $97.49M | $31.20M | $68.60M | $18.60M | $3.08M | $3.12M | $53.16M | $17.48M |
| QoQ Change | — | -100.0% | — | — | -100.0% | — | — | — | -20.7% | +981.0% | -68.0% | +119.9% | -72.9% | -83.5% | +1.5% | >999% | -67.1% |
| YoY Change | — | — | — | — | — | — | — | -8.3% | — | — | — | +503.1% | +106.2% | -96.8% | -90.0% | -22.5% | -6.0% |
Range$0.00 – $97.49M
CAGR+41.9%
Avg YoY Growth+55.1%
Median YoY Growth-8.3%
Other accrued liabilities at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's other accrued liabilities?
- Royalty Pharma (RPRX) reported other accrued liabilities of $17.48M in Q1 2026.
- How has Royalty Pharma's other accrued liabilities changed year-over-year?
- Royalty Pharma's other accrued liabilities decreased by 6.0% year-over-year, from $18.60M to $17.48M.
- What is the long-term trend for Royalty Pharma's other accrued liabilities?
- Over 5 years (2020 to 2025), Royalty Pharma's other accrued liabilities has grown at a 23.4% compound annual growth rate (CAGR), from $18.60M to $53.16M.
- What does other accrued liabilities mean?
- Miscellaneous short-term debts or obligations not covered by other standard categories.